FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3037134987> ?p ?o ?g. }

• W3037134987 endingPage "103879" @default.
• W3037134987 startingPage "103879" @default.
• W3037134987 abstract "Herpes zoster (HZ), commonly called shingles, it is a distinctive syndrome caused by reactivation of varicella zoster virus (VZV). A better understanding of the biological characteristics of HZ patients can help develop new targeted therapies to improve the prognosis. High-throughput proteomics technology can deeply study the molecular changes in the development and progression of HZ disease and integrate different levels of information, this is important to help make clinical decisions. Circulating blood contains a lot of biological information, we conducted a proteomics study of patient plasma, hoping to identify key proteins that could indicate the development of HZ. Compared to healthy human plasma, we found 44 differentially expressed proteins in the plasma of HZ patients, the main pathways involved in these molecules are MAPK signaling pathway, Neuroactive ligand-receptor interaction, Acute myeloid leukemia, Transcriptional misregulation in cancer. We found that 27 proteins have direct protein-protein interactions. Based on the comprehensive score, we identified six key molecules as candidate molecules for further study, and then validated another 80 plasma samples (40 HZ patient plasma and 40 healthy human plasma) using enzyme-linked immunosorbent assay (ELISA), immunoblot assay and receiver operating characteristic (ROC) curve analysis. Finally, we found that the expression levels of these three proteins (PLG, F2, VTN) were significantly lower than those of healthy controls (P < .05). To the best of our knowledge, we first used tandem mass tag (TMT) combined with liquid chromatography-mass spectrometry (LC-MS/MS) to screen for differentially expressed proteins in plasma between HZ patients and healthy individuals. It is preliminarily proved that the plasma protein expression profile of HZ patients is different from that of uninfected patients, it has also been found that these three altered key proteins may be used as biomarkers to test early HZ infection. This study reveals new insights into HZ that help to more accurately identify early HZ patients and to find new therapeutic targets. Varicella-zoster virus (VZV; termed human alphaherpesvirus 3 by the International Committee on Taxonomy of Viruses) is a herpesvirus that is ubiquitous in humans and can cause chickenpox and herpes zoster (HZ). After the initial infection of varicella, the VZV goes into a dormant state in the sensory ganglia and cranial nerves. As age or immunosuppression increases, the cellular immunity to VZV decreases, and the virus reactivates and spreads along the sensory nerves to the skin, causing a unique prodromal pain followed by a rash. About one in five people around the world may be infected with VZV at some point in their lives. According to statistics, about one-third of infected people will develop HZ in their lifetime, and an estimated 1 million cases of herpes zoster occur in the United States each year. Herpes zoster can occur at any age and is usually less severe in children and young adults, but the greatest morbidity and mortality are observed in elderly and immunocompromised patients. 20% of patients with HZ have complications including vasculitis, increased risk of myocardial infarction, or postherpetic neuralgia, the overall mortality rate of patients with HZ in the United States is close to 5%. Considering the wide clinical severity and complications of this disease, there is a great need for biomarkers that contribute to early diagnosis, classification of risks, and prediction of outcomes, which will help elucidate the mechanisms underlying their clinical development. As a useful tool in biology, quantitative proteomics can repeatedly identify and accurately quantify proteins in a variety of biological samples. Proteomic analysis focuses on translational proteins, which play a direct role in most biological processes. Although a small number of proteins can be studied simultaneously with traditional methods, such as ELISA and Western blotting, typical proteomics studies can simultaneously analyze thousands of proteins for a more comprehensive identification. Proteomics has been successfully applied to human-based disease research, Analysis of exposed and unexposed subjects based on mass spectrometry (MS) has been found to reveal altered expression of proteins that can be identified as intermediate biomarkers of early disease effects. Tandem mass tags (TMTs) are chemical labels used for MS-based identification and quantification of biological molecules. TMTs play an important role in proteomic analysis in a variety of samples such as cells, tissues, and body fluids. The body fluids that are often detected clinically are blood, which are easy to obtain and contain abundant biological information related to physiological and pathological processes, we hope to develop protein biomarkers from these blood. Therefore, in order to better characterize the pathological process of HZ patients, we performed proteomic analysis of HZ patients and healthy human plasma using the TMT method. This comparison aims to identify specific processes in the development of HZ disease through protein profiling, which may help to improve our biological understanding of HZ." @default.
• W3037134987 created "2020-07-02" @default.
• W3037134987 creator A5007941824 @default.
• W3037134987 creator A5008222650 @default.
• W3037134987 creator A5023777160 @default.
• W3037134987 creator A5033707023 @default.
• W3037134987 creator A5044351940 @default.
• W3037134987 creator A5048402004 @default.
• W3037134987 creator A5049044395 @default.
• W3037134987 creator A5063051049 @default.
• W3037134987 creator A5070346689 @default.
• W3037134987 creator A5081093007 @default.
• W3037134987 date "2020-08-01" @default.
• W3037134987 modified "2023-10-11" @default.
• W3037134987 title "Quantitative proteomic analysis of human plasma using tandem mass tags to identify novel biomarkers for herpes zoster" @default.
• W3037134987 cites W1484931749 @default.
• W3037134987 cites W1608557519 @default.
• W3037134987 cites W1715347290 @default.
• W3037134987 cites W1965723799 @default.
• W3037134987 cites W1974116356 @default.
• W3037134987 cites W1978529901 @default.
• W3037134987 cites W1985636847 @default.
• W3037134987 cites W1989469055 @default.
• W3037134987 cites W1992253326 @default.
• W3037134987 cites W1993203805 @default.
• W3037134987 cites W1997634298 @default.
• W3037134987 cites W1998398903 @default.
• W3037134987 cites W1998767819 @default.
• W3037134987 cites W2004216768 @default.
• W3037134987 cites W2006224584 @default.
• W3037134987 cites W2017613799 @default.
• W3037134987 cites W2019605417 @default.
• W3037134987 cites W2025551088 @default.
• W3037134987 cites W2030072196 @default.
• W3037134987 cites W2036930114 @default.
• W3037134987 cites W2037199116 @default.
• W3037134987 cites W2056650621 @default.
• W3037134987 cites W2062529150 @default.
• W3037134987 cites W2065607713 @default.
• W3037134987 cites W2068520355 @default.
• W3037134987 cites W2071141883 @default.
• W3037134987 cites W2073086343 @default.
• W3037134987 cites W2078541138 @default.
• W3037134987 cites W2084384135 @default.
• W3037134987 cites W2091217595 @default.
• W3037134987 cites W2091448229 @default.
• W3037134987 cites W2096814450 @default.
• W3037134987 cites W2113240223 @default.
• W3037134987 cites W2114509436 @default.
• W3037134987 cites W2116308765 @default.
• W3037134987 cites W2117506103 @default.
• W3037134987 cites W2120284993 @default.
• W3037134987 cites W2124824093 @default.
• W3037134987 cites W2138760592 @default.
• W3037134987 cites W2143930683 @default.
• W3037134987 cites W2205622261 @default.
• W3037134987 cites W2558110221 @default.
• W3037134987 cites W2624860380 @default.
• W3037134987 cites W2807541122 @default.
• W3037134987 doi "https://doi.org/10.1016/j.jprot.2020.103879" @default.
• W3037134987 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32585426" @default.
• W3037134987 hasPublicationYear "2020" @default.
• W3037134987 type Work @default.
• W3037134987 sameAs 3037134987 @default.
• W3037134987 citedByCount "9" @default.
• W3037134987 countsByYear W30371349872021 @default.
• W3037134987 countsByYear W30371349872022 @default.
• W3037134987 countsByYear W30371349872023 @default.
• W3037134987 crossrefType "journal-article" @default.
• W3037134987 hasAuthorship W3037134987A5007941824 @default.
• W3037134987 hasAuthorship W3037134987A5008222650 @default.
• W3037134987 hasAuthorship W3037134987A5023777160 @default.
• W3037134987 hasAuthorship W3037134987A5033707023 @default.
• W3037134987 hasAuthorship W3037134987A5044351940 @default.
• W3037134987 hasAuthorship W3037134987A5048402004 @default.
• W3037134987 hasAuthorship W3037134987A5049044395 @default.
• W3037134987 hasAuthorship W3037134987A5063051049 @default.
• W3037134987 hasAuthorship W3037134987A5070346689 @default.
• W3037134987 hasAuthorship W3037134987A5081093007 @default.
• W3037134987 hasBestOaLocation W30371349871 @default.
• W3037134987 hasConcept C104317684 @default.
• W3037134987 hasConcept C146543888 @default.
• W3037134987 hasConcept C153911025 @default.
• W3037134987 hasConcept C170493617 @default.
• W3037134987 hasConcept C185592680 @default.
• W3037134987 hasConcept C46111723 @default.
• W3037134987 hasConcept C55493867 @default.
• W3037134987 hasConcept C60644358 @default.
• W3037134987 hasConcept C70721500 @default.
• W3037134987 hasConcept C80311884 @default.
• W3037134987 hasConcept C86153913 @default.
• W3037134987 hasConcept C86803240 @default.
• W3037134987 hasConceptScore W3037134987C104317684 @default.
• W3037134987 hasConceptScore W3037134987C146543888 @default.
• W3037134987 hasConceptScore W3037134987C153911025 @default.
• W3037134987 hasConceptScore W3037134987C170493617 @default.
• W3037134987 hasConceptScore W3037134987C185592680 @default.
• W3037134987 hasConceptScore W3037134987C46111723 @default.

• next